Maintenance Therapy for Multiple Myeloma

This page is for people with multiple myeloma who are being offered maintenance therapy, and their families. It explains what the trials show, the risks, and the main drug choices.

After induction treatment (the first, more intensive phase), and often after a stem cell transplant, the M protein in your blood (an abnormal protein made by myeloma cells) falls and then flattens out. NCI describes this plateau directly: once it is reached, more treatment at conventional doses does not push the number lower.

That plateau is what raised the question maintenance answers. If more intensive treatment adds nothing, does a low, tolerable, continuous dose keep the disease down for longer?

NCI notes a gap in the evidence. No trial has directly compared consolidation, a short extra burst, against maintenance, a long low dose. Most trials use one or both without testing them head to head.

Lenalidomide is the standard. Its label lists maintenance after autologous stem cell transplant as an approved use: a capsule taken at home on a repeating monthly pattern.

The amount, and whether you take it every day or with a break each cycle, differ between people and can change over time — the label allows a step up after a few cycles if the start is tolerated, and NCI notes a range of patterns in use. All of that lives in your own myeloma team's prescription. If the capsules or the pattern in your pack ever differ from what you expected, call the team before taking anything.

There is no fixed stopping date in the label. Maintenance generally continues until the myeloma progresses or the side effects become unacceptable. Multiple myeloma covers the treatment sequence this sits at the end of.

This is where the honest picture matters. Two measures do not move together here. One is PFS, or progression-free survival, the time before the myeloma grows again. The other is OS, or overall survival, the time people live.

A trial of 460 people after induction and transplant compared lenalidomide maintenance with placebo. At 91 months of follow-up, median OS was 113.8 months with the drug and 84.1 months with placebo. The 5-year OS rate was 76% versus 64%.

A pooled analysis of 1,208 transplant patients found median OS not reached on lenalidomide. It was 86 months with placebo or watching. The hazard ratio was 0.75.

Now the other side. A trial of 1,917 people, with and without transplant, found median PFS of 39 months versus 20 months. But 3-year OS did not differ: 78.6% versus 75.8%. A pooled analysis of 7,730 patients, on lenalidomide or thalidomide maintenance, found the same split. PFS clearly improved. OS did not. A third pooled analysis of 5,073 patients matched that result.

NCI sums it up bluntly. Every trial and pooled analysis of lenalidomide maintenance improved PFS. OS improved in one trial and one pooled analysis, both after a transplant.

So the benefit is best supported when maintenance follows a transplant. Without one, the case rests mostly on delaying relapse rather than on living longer. That is a reasonable goal. It is just a different goal.

NCI states that all the lenalidomide maintenance trials showed an increase in myelodysplasia or acute leukemia, from 3% to 7%. That risk is mostly concentrated in people previously exposed to alkylating agents such as melphalan.

The lenalidomide label carries three boxed warnings. The first is embryo-fetal toxicity: lenalidomide is a thalidomide analogue and caused limb abnormalities in monkeys. Because of this it is distributed only through a restricted program called the Lenalidomide REMS. The second is hematologic toxicity, meaning low neutrophils and low platelets. The third is venous and arterial thromboembolism, with an explicit recommendation for anti-clotting prophylaxis in myeloma patients receiving lenalidomide with dexamethasone.

By contrast, the ixazomib maintenance trial reported no increase in second cancers, at 3% in both the drug and placebo groups.

Ixazomib is a proteasome inhibitor taken by mouth. One trial enrolled 656 people who had at least a partial response after induction and transplant. Median PFS was 26.5 months with ixazomib and 21.3 months with placebo. NCI calls it a reasonable option for people who cannot take lenalidomide.

Daratumumab is an antibody against CD38. The CASSIOPEIA trial tested it as maintenance after transplant. Median PFS was not reached in that arm. It was 46.7 months with watching alone.

The AURIGA trial took a narrower group of 200 people. All had reached a very good partial response or better. All were still MRD-positive at 10 to the minus 5 in the marrow. MRD, or minimal residual disease, means a very small number of myeloma cells can still be found. None had received an anti-CD38 drug during induction. Adding daratumumab to lenalidomide gave a 30-month PFS of 82.7%, against 66.4% for lenalidomide alone. MRD turned negative at 10 to the minus 6 in 23.2% versus 5.0%. The cost showed up elsewhere. Grade 3 or 4 low blood counts hit 54.2% versus 46.9%. Infections hit 18.8% versus 13.3%.

NCI adds an important limit: the extra value of daratumumab maintenance in people who already received daratumumab during induction has not been established.

The Myeloma XI trial looked at 556 people with del(1p), del(17p), or t(4;14). Median PFS was 57.3 months with lenalidomide maintenance. It was 10.9 months with watching. That gap is far wider than in standard-risk disease.

For very high-risk features, especially del(17p) or t(14;16), NCI notes that bortezomib maintenance, with or without lenalidomide, may be required, but states plainly that this approach is not evidence-based and needs confirmatory trials. If it is offered, that is the honest footing it stands on.

Many people reasonably ask whether an undetectable MRD result means they can stop. NCI addresses this head on and says there are no data suggesting that sustained MRD negativity allows maintenance to be reduced or stopped. What MRD means explains the thresholds behind those results.

NCI also names a barrier that trials rarely measure: short-term toxicity, long-term toxicity, and financial toxicity may all prevent maintenance from being carried out as planned. Cost is a legitimate reason to revisit the plan, not a private failure.

• Call 911 or go to an emergency department if sudden or new breathlessness or chest pain begins. Lenalidomide raises the risk of a clot reaching the lungs, and its label says to seek immediate medical care for signs of a clot. Do not drive yourself.
• Get medical care right away (call your myeloma team, or go to an emergency department if you cannot reach them) if one arm, calf or thigh becomes swollen, warm, and painful. That is the other face of the same clot risk.
• Treat a temperature of 100.4 degrees F (38 C) as an emergency, not a same-day call. Lenalidomide can cause low neutrophil counts, so ring your myeloma team on their urgent line the moment you see that reading, whatever the hour. If nobody answers quickly, go to an emergency department and tell them you are on myeloma treatment. CDC says to call your doctor immediately for a fever during chemotherapy.
• Call your myeloma team right away if a rash spreads quickly, blisters, or involves the mouth or eyes.
• Call your myeloma team within a day or two if new bone pain wakes you at night, a new area turns tender, you bruise easily, or you bleed from the gums. If bleeding will not stop, call your team right away; for emergencies call 911 or go to the ER.

• https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
• https://www.cancer.gov/about-cancer/treatment/side-effects/infection
• https://medlineplus.gov/ency/patientinstructions/000913.htm